人前蛋白转化酶枯草溶菌素9抑制剂在高脂血症及高血压中的研究现状

Abstract
Figure/Table
References (27)
Related Citation (15)

Download: PDF (695 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Cardiovascular and cerebrovascular disease (CVD) is a serious threat to human health. Among them, cholesterol, especially low-density lipoprotein cholesterol (LDL-C), is closely related to the pathogenesis. The current guidelines recommend statins as the first choice for LDL-C control, Howerer, some data showed that after taking can appear a variety of adverse reactions. In recent years, human proprotein invertase subtilis 9 (PCSK9) has been found to have a close correlation with LDL-C. At present, a large number of studies have proved that PCSK9 inhibitors can reduce the level of LDL-C in blood, and even have the opportunity to be applied in the antihypertensive therapy. In this paper, the research status of PCSK9 inhibitors in hyperlipidemia and hypertension was systematically reviewed.

Key words： Low-density lipoprotein cholesterol Hypertension Human proprotein invertase subtilis 9 Human proprotein-converting enzyme subtilis 9 inhibitor

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Lu LI Jing▲

Cite this article:

CHEN Lu LI Jing▲. Research status of human proprotease subtilis 9 inhibitor in hyperlipidemia and hypertension[J]. 中国医药导报, 2019, 16(12): 42-45.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I12/42

[1] 王恺隽，李铁威，蔺亚晖，等.小而密低密度脂蛋白胆固醇与冠状动脉粥样硬化特征的相关性分析[J]临床检验杂志，2017，35（9）：674-679.
[2] Nishikura T，Koba S，Yokota Y，et al. Elevated small dense lowdensity lipoprotein cholesterol as a predictor for future cardiovascular events in patients with stable coronary artery disease [J]. J Atheroscler Thromb，2014，21（8）：755-767.
[3] 中国成人血脂异常防治指南修订联合委员会.中国成人血脂异常防治指南（2016年修订版）[J].中国循环杂志，2016，31（10）：937-950.
[4] Barkas F，Liberopoulos E，Klouras E，et al. Attainment of muhifactorial treatment targets among the elderly in a lipid clinic [J]. J GeriatrCardiol，2015，12（3）：239-245.
[5] Livingstone SJ，Looker HC，Akbar T，et al. Effect of atorvastatin on glycaemia progression in patients with diabetes：an analysis from the Collaborative Atorvastatin in Diabetes Trial（CARDS） [J]. Diabetologia，2016，59（2）：299-306.
[6] Poirier S，Mayer G，Benjannet S，et al. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor（LDLR）and its closest family members VLDLR and ApoER2 [J]. J Korean Soc Appl Bi，2008，283（4）：2363-2372.
[7] Chaudhary R，Garg J，Shah N，et al. PCSK-9 inhibitors：A new era of lipid lowering therapy [J]. World J Cardiol，2017，9（2）：76-91.
[8] Dong B，WU M，Li H，et al. Strong induction of PCSK9 gene expression through HNFlalpha and SREBP2：mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters [J]. J Lipid Res，2010， 51（6）：1486-1495.
[9] Wu NQ，Li JJ. PCSK9 gene mutations and low-density lipoprotein cholesterol [J]. Clin Chim Acta，2014，431：148-153.
[10] Van Poelgeest EP，Hodges MR，Moerland M，et al. Antisense-mediated reduction of proprotein convertase subtilisin／kexin type 9 （PCSK-9）：a first - in - human randomized，placebo - controlled tria [J]. Br J Clin Pharmacol，2015，80（6）：1350-1361.
[11] Rashid H，Meredith IT，Nasis A. PCSK9 Monoclon′al Antibodies in 2016：Current Status and Future Challenges [J]. Heart Lung Circ，2017，26（28）：786-798.
[12] Raal FJ，Stein EA，Dufour R，et al. PCSK-9 inhibition with evolocumab（AMG 145）in heterozygousfamilial hypercholesterolaemia （RUTHERFORD-2）：a randomised，double - blind，placebo - controlled trial [J]. Lancet，2015，385（9965）：331-340.
[13] Fitzgerald K，Frank-Kamenetsky M，Shulga-Morskaya S，et al. Effect of an RNA interference drug oil the synthesis of proprotein convertase subtilisin／kexin type 9（PCSK9） and the concentration of serum LDL cholesterol in healthy volunteers：a randomized，single-blind，placebo-controlled，phase1 trial [J]. Lancet，2014，383（9911）：60-80.
[14] Lindholm MW，Elmén J，Fisker N，et al. PCSK - 9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates [J]. Mol Ther，2012， 20（2）：376-381.
[15] Durairaj A，Sabates A，Nieves J，et al. Proprotein Convertase Subtilisin/Kexin Type 9（PCSK9）and Its Inhibitors：a Review of Physiology，Biology，and Clinical Data [J]. Curr Treat Options Cardio Med，2017，19（58）：57-68.
[16] Sabatine MS，Giugliano RP，Keech AC，et al. Evolocumab and clinical outcomes in patients with cardiovascular disease [J]. N Enql J Med，2017，376（18）：1713-1722.
[17] Nordestgaard B，Chapman M，Humphries S，et al. Familial hypercholesterolemia is underdiagnosed and undertreated in the general population：guidance for clinicians to prevent coronary heart disease：consensus statement of European Atherosclerosis Society [J]. Eur Heart J，2013， 34（45）：3478-3490.
[18] Sabatine MS，Giugliano RP，Wiviott SD，et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events [J]. N Engl J Med，2015，372（16）：1500-1509.
[19] 刘倩，李言洵，胡志灏，等.PCSK9基因rs2479409位点多态性与认知障碍相关[J].基础医学与临床，2017，37（12）：1687-1690.
[20] Poirier S，Prat A，Marcinkiewicz E，et al. Implication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous system [J]. J Neurochem，2006，98（3）：838-850.
[21] Kang S，Jeong H，Baek JH，et al. PiB-PET imaging-based serum proteome profiles predict mild cognitive impairment and Alzheimer′s disease [J]. J Alzheimers Dis，2016，53（4）：1563-1576.
[22] Saeed A，Virani SS，Jones PH，et al. Case reports of proprotein convertase subtilisin/kexin type 9（PCSK9） inhibition nonresponse [J]. J Clin Lipidol，2018，12（5）：1141-1145.
[23] Pavlakou P，Liberopoulos E， Dounousi E，et al. PCSK9 in chronic kidney disease [J]. Int Urol Nephrol，2017，49（6）：1015-1024.
[24] Sharotri V，Collier DM，Olson DR，et al. Regulation of epithelial sodium channel trafficking by proprotein convertase subtilisin/kexin type 9 （PCSK9） [J]. J.Biol. Chem，2012，287（23）：19266-19274.
[25] Cariou B，Si-Tayeba K，Le May C. Role of PCSK9 beyond liver involvement [J]. Curr Opin Lipidol，2015，26（3）：155-161.
[26] Edelheit O，Hanukoglu I，Gizewska M，et al. Novel mutaions in epithelial sodium channel（EnaC） subunit genes and phenotypic expression of multisystem pseudohypoaldosteronism [J]. Clin Endocrinol（Oxf），2005，62（2）：547-553.
[27] Cariou B，Le Bras M，Langhi C，et al. Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients [J]. Atherosclerosis，2010，211（2），700-702.